Avalo Therapeutics (NASDAQ:AVTX) reported its Q3 earnings results on Thursday, November 9, 2023 at 07:00 AM.
Here's what investors need to know about the announcement.
Earnings
Avalo Therapeutics beat estimated earnings by 90.0%, reporting an EPS of $-0.11 versus an estimate of $-1.1.
Revenue was down $14.71 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.21 which was followed by a 11.53% drop in the share price the next day.
Here's a look at Avalo Therapeutics's past performance:
| Quarter | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.80 | -0.97 | -0.73 | -1.09 |
| EPS Actual | -0.59 | -0.85 | -1.04 | 0.34 |
| Revenue Estimate | 500K | 1.00M | 3.61M | 1.08M |
| Revenue Actual | 643K | 475K | 896K | 14.95M |
** Listen to the earnings announcement yourself by clicking here. **
To track all earnings releases for Avalo Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
